New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LEU CLL - acalabrutinib

LEU CLL - acalabrutinib

Treatment Overview

Cycle 1 (and all further cycles) - 28 days

Cycle length:
28

Cycle details

Cycle 1 (and all further cycles) - 28 days

Medication Dose Route Days Max Duration
acalabrutinib 100 mg Twice daily oral administration 1 to 28

Full details

Cycle 1 (and all further cycles) - 28 days

Day: 1

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 2

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 3

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 4

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 5

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 6

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 7

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 8

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 9

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 10

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 11

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 12

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 13

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 14

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 15

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 16

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 17

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 18

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 19

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 20

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 21

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 22

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 23

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 24

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 25

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 26

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 27

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Day: 28

Medication Dose Route Max duration Details
acalabrutinib 100 mg Twice daily oral administration
Instructions:
Take each dose approximately 12 hours apart. Swallow whole with a glass of water, do not crush, chew or open capsule. Avoid antacids at least 2 hours before or after taking this medicine.

Supportive Care Factors

Factor Value
Antiviral prophylaxis for herpes virus: Routine antiviral prophylaxis may be considered
Emetogenicity: Minimal to low
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: Routine antibiotic prophylaxis may be considered
Tumour lysis syndrome prophylaxis: Tumour lysis syndrome prophylaxis may be considered

Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.

References

Ghia, P., A. Pluta, M. Wach, et al. 2020. "ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia." J Clin Oncol:JCO1903355., PMID: 32459600

Byrd, J. C., B. Harrington, S. O'Brien, et al. 2016. "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia." N Engl J Med 374(4):323-332., PMID: 26641137

Byrd, J. C., W. G. Wierda, A. Schuh, et al. 2020. "Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results." Blood 135(15):1204-1213., PMID: 31876911

Sharman, J. P., M. Egyed, W. Jurczak, et al. 2020. "Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial." Lancet 395(10232):1278-1291., PMID: 32305093

Gaidano, G. and D. Rossi. 2017. "The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment." Hematology Am Soc Hematol Educ Program 2017(1):329-337., PMID: 29222275

AstraZeneca Limited. Calquence New Zealand Datasheet 12 August 2021. https://www.medsafe.govt.nz/Profs/Datasheet/c/calquencecap.pdf (accessed 14 December 2021).

Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, Howell J, Hajkowicz K, Nandurkar H, Johnston A, Bak N, Thompson AJ. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Med J Aust. 2019 Jun;210(10):462-468. doi: 10.5694/mja2.50160. Epub 2019 May 19., PMID: 31104328

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.